Pfizer will list its COVID-19 treatment Paxlovid at a price of $1,390 per five-day course when it soon hits the commercial market, the drugmaker confirmed to Axios.
Why it matters: Paxlovid’s new listed price, first reported by the Wall Street Journal, will be more than twice the $529 paid by the federal government, which until now has maintained the entire U.S. supply of the key antiviral medication.
Quite a bit of hyperbole there. 'Sides, vaccination is still free…
Among the 38,689 adults in the fully vaccinated, boosted group who were not treated with Paxlovid there were 143 hospitalizations (0.37%) and seven deaths (.02%).